Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $224.30M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.45M
Average 0.49M
BCYC Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Bicycle Therapeutics plcNASDAQ: BCYC
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -7394.5%
Operating margin was -7394.5% in Q1 FY2026, down 6690.8 pp from a year earlier. On a trailing-twelve-month basis it was -381.8%, up 583.8 pp year over year. Over 3 fiscal years it widened by 465.3 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 7 analysts of -416.6% for the fiscal year ending Dec 2026, down from -341.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -7394.5%-7343.1 pp QoQ
- Last fiscal yearDec 2025
- -341.3%+253.7 pp YoY
- LTMMar 2026
- -381.8%+583.8 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -341.3%
- Year-over-year change
- +253.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -341.3% | +253.7pp |
| FY2024 | 2024-12-31 | -595.0% | +109.2pp |
| FY2023 | 2023-12-31 | -704.1% | +102.4pp |
| FY2022 | 2022-12-31 | -806.6% | -245.6pp |
| FY2021 | 2021-12-31 | -561.0% | — |
Operating Margin vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 operating margin of -381.8% is the 6th highest of the 7 companies compared; the peer median is -176.6%.
- Its year-over-year change of +583.8 pp is the 2nd highest of 5, against a peer median of +274.8 pp.
- Over three fiscal years its change of +465.3 pp compares with a peer median of +1627.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -34.8% | +533.8 pp | +72391.0 pp | |
| LTM Dec 2025 | -120.8% | — | — | |
| LTM Mar 2026 | -149.6% | +15.9 pp | -74.5 pp | |
| LTM Mar 2026 | -203.5% | +883822.6 pp | +3329.3 pp | |
| LTM Mar 2026 | -217.9% | -117.5 pp | -1661.8 pp | |
| LTM Mar 2026 | -381.8% | +583.8 pp | +465.3 pp | |
| LTM Mar 2026 | -1063.9% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding BCYC) | -176.6% | +274.8 pp | +1627.4 pp | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| Weighted Avg Shares | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
| Weighted Avg Shares (Diluted) | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.